We Can Prevent the Bankruptcy of the Sacred – Dare we Try?
Religious leaders. Credit: UN Photo/Rick BajornasBy Azza KaramNEW YORK, Jul 22 2021 (IPS) The UN High Level Political Forum (HLPF) came to a conclusion on July 15th. Another HLPF, another series of declaration, and commitments and concerns articulated by governments. All of which are besieged by the combined pandemics of institutional and systemic failures, increasing violence, global warming which has already led to the deaths of species and humans, and of course, Covid-19 and the utter shame of only the rich getting vaccinated. And the results of this High Level Political Forum? Not the dramatic changes that our plane...
Source: IPS Inter Press Service - Health - July 22, 2021 Category: International Medicine & Public Health Authors: Azza Karam Tags: COVID-19 Featured Global Headlines Health Human Rights Humanitarian Emergencies Inequity TerraViva United Nations Women's Health Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Hope, horror and Covid-19: my 23 years as the Guardian ’s health correspondent | Sarah Boseley
I ’ve travelled the world covering everything from HIV to MMR to Ebola… and then Covid came along. These are stories that changed me – and the worldShe was tall, wrapped in a green patterned dress that clung to her legs and ended just above dusty flip-flops. In the bustling, sweltering market, Grace Mathanga looked at me appraisingly, as if to say: “What have we here?” And I knew she was the one.It was the end of2002. I had flown to Lilongwe, the capital of Malawi, with excitement in my heart and fear of failure eating at my gut. I ’d been the Guardian’s health correspondent for a...
Source: Guardian Unlimited Science - July 17, 2021 Category: Science Authors: Sarah Boseley Tags: Health Coronavirus Aids and HIV Infectious diseases Vaccines and immunisation Society Ebola Africa Epidemics World news Global health Global development Campaigning journalism Newspapers & magazines Media Source Type: news

Knowledge of infection prevention and control among healthcare workers and factors influencing compliance: a systematic review
Conclusion: Embracing a multifaceted approach towards improving IPC-intervention strategies is highly suggested. The goal being to improve compliance among HCWs with IPC measures is necessary. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 16, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., July 14, 2021 – Interim results from a Phase 1/2a sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization, the length of time evaluated to date. Data showed that T-cell responses – including the important CD8+ T-cells that seek out and destroy infected cells – persisted over the eight-month timeframe examined. The Company announced topline preprint study results from...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

New study provides data on protections of ebola vaccines
This study identifies features of the antibody response responsible for survival from 139 immune- and vaccine-related parameters.* Findings will help develop vaccines that produce an antibody response profile which ensures protection and focuses on survival quality (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 14, 2021 Category: Infectious Diseases Source Type: news

Liberia: Health Workers to Take Ebola. Vaccine
[New Republic] The government of Liberia and its partner- the World Health Organization said they will begin administering Ebola vaccination to health workers, Immigration and members of Liberia Drugs Enforcement officers working near the borders of Guiana. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 13, 2021 Category: African Health Source Type: news

Johnson & Johnson Launches Network of Global Health Discovery Centers that Aim to Speed Up Science and Tackle Pandemic Threats
NEW BRUNSWICK, N.J., July 9, 2021 – Johnson & Johnson (the Company) today announced the launch of the J&J Centers for Global Health Discovery (J&J Centers), a new, global network of unique research partnerships that will leverage the institutional strengths of Johnson & Johnson and leading academic institutions to accelerate discovery research to address the world’s most pressing global health challenges. The first J&J Satellite Center for Global Health Discovery (Satellite Center) was launched at the London School of Hygiene & Tropical Medicine (LSHTM) at an event co-hosted by Johnson &...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine ...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Preventing the Next Health Crisis Depends on Health Workers. We Need 18 Million More
Over 115,000 health and care workers died during the COVID-19 pandemic. As a physician who’s cared for patients with COVID-19, malaria and Ebola, I’ve seen too many colleagues make the ultimate sacrifice on the frontlines. I’m not surprised experts responding to TIME’s survey ranked bolstering the world’s public health workforce, particularly in rural and remote regions, as one of the top five of nearly 50 strategies to prepare for the next pandemic. But I’m concerned they ranked this the least feasible strategy amongst the top five. Experts ranked high the need for new systems to raise ...
Source: TIME: Health - June 10, 2021 Category: Consumer Health News Authors: Raj Panjabi Tags: Uncategorized COVID-19 health Magazine Source Type: news

Johnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities
NEW BRUNSWICK, N.J., June 9, 2021 – Johnson & Johnson (NYSE: JNJ) today published the 2020 Health for Humanity Report (Report), which serves as the Company’s annual disclosure on environmental, social and governance (ESG) performance and illustrates progress toward fulfilling its corporate purpose to change the trajectory of health for humanity. The Report documents the Company’s performance and provides information on how the Company generates long-term social, environmental and economic value for all stakeholders; provides an accounting of the final year of progress against the Johnson & Johnson...
Source: Johnson and Johnson - June 9, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

The U.S. Can and Should Vaccinate Every Health Care Worker in the World
As the United States seems close to controlling a pandemic that has killed 600,000 Americans, we must recognize that in much of the rest of the world, the pandemic continues to rage. Now, with the U.S. vaccine supply far outstripping our domestic needs, the U.S. is taking action, with President Biden’s announcement of the first major global distribution of American vaccine doses. But there are billions of vulnerable people around the world, and at current vaccination rates many will be waiting a long time for a shot. Health care workers around the globe should not be left waiting. As its first major global vaccinatio...
Source: TIME: Health - June 4, 2021 Category: Consumer Health News Authors: Dr. Ashish K. Jha Tags: Uncategorized COVID-19 Source Type: news

Statement on the SAGE Recommendation Regarding the Johnson & Johnson Ebola Vaccine Regimen
New Brunswick, NJ (June 4, 2021) – Johnson & Johnson welcomes the recommendation by the Strategic Advisory Group of Experts (SAGE) on Immunization for the World Health Organization (WHO) in support of the use of Johnson & Johnson’s two-dose Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), both during outbreaks for individuals at some risk of Ebola exposure and preventively, before outbreaks, for national and international first responders.This is an important milestone for our Ebola vaccine and our mission to help prevent and control Ebola outbreaks. It follows Marketing A...
Source: Johnson and Johnson - June 4, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Ervebo (Ebola Zaire Vaccine, Live Suspension for Intramuscular Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 25, 2021 Category: Drugs & Pharmacology Source Type: news

Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
Discussions are ongoing with the U.S. Food and Drug Administration regarding the approval of the vaccine regimen in the U.S. WHO Prequalification is often a prerequisite for national registrations of new vaccines and medicines in developing countries. Johnson & Johnson now looks forward to collaborating with the WHO’s African Vaccine Regulatory Forum (AVAREF) to progress national registrations of the Company’s Ebola vaccine regimen. The Company’s Ebola vaccine regimen is designed to be used proactively to induce immunity against Ebola virus disease in adults and children. Johnson & Johnson’s...
Source: Johnson and Johnson - May 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

New ebolavirus vaccine design seeks to drive stronger antibody defense
(Scripps Research Institute) Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses that continue to threaten global health. In the new design, described in a paper in Nature Communications, copies of the Ebola virus outer spike protein, known as the glycoprotein, are tethered to the surface of a spherical carrier particle. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 12, 2021 Category: Infectious Diseases Source Type: news

One Health Approach Key to Tackling Africa ’s Challenges
COVID-19 has shown that we need to act fast as changes at the interface of humans, livestock and wildlife are driving increased risk of emerging disease threats across the globe. Credit: Marc-André Boisvert/IPSBy Olanike AdeyemoIBADAN, Nigeria, May 11 2021 (IPS) The COVID-19 pandemic has shown us that global health challenges cannot be solved only by health sector interventions. Many of the recent epidemics — Ebola, Zika and even Covid-19 — are emerging infectious diseases transmissible from wildlife species. In addition, other global health challenges greatly impact people, livestock, wildlife and agri...
Source: IPS Inter Press Service - Health - May 11, 2021 Category: International Medicine & Public Health Authors: Olanike Adeyemo Tags: Africa Headlines Health TerraViva United Nations Source Type: news

How West African Leaders Can Tackle Youth and Gender Inequities
Women informal cross-border traders. Credit: Trevor Davies/IPSBy Ifeanyi Nsofor, Adaeze Oreh, and John Lazame TindabilMay 6 2021 (IPS) Recently, both Republics of Benin and Chad held their 2021 national elections. These countries are among thirteen countries on the continent billed to elect new political leaders in 2021 alone. This is a good opportunity to improve conditions on the continent. Indeed, the COVID-19 pandemic has magnified other issues on the continent like youth unemployment that better leadership could help improve. These are three ways West African leaders can better help their nations at thi...
Source: IPS Inter Press Service - Health - May 6, 2021 Category: International Medicine & Public Health Authors: Ifeanyi Nsofor, Adaeze Oreh, and John Lazame Tindabil Tags: Africa Gender Global Governance Headlines Health Poverty & SDGs Source Type: news

Congo-Kinshasa: Vaccine Credited with Containing Ebola Outbreak
[DW] Six people have died of the Ebola virus in DR Congo's eastern province of North Kivu in recent months. UNICEF is cautiously optimistic that virus has been brought under control from a vaccine developed by Merck. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 4, 2021 Category: African Health Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participa...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for eve...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Ebola Cluster Traced to Vaccinated Taxi Driver Who Appeared to Recover Ebola Cluster Traced to Vaccinated Taxi Driver Who Appeared to Recover
This is the story of a taxi driver, a vaccine that may not live up to its billing, and a treatment that seemed to save him from death, only to set the stage for his infection to spread to 91 others in six communities over 4 months.Reuters Health Information (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - April 1, 2021 Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news

Getting One Vaccine Is Good. How About Mix-and-Match?
Researchers are exploring the possible benefits of pairing doses from two different Covid-19 vaccines. (Source: NYT Health)
Source: NYT Health - March 30, 2021 Category: Consumer Health News Authors: Carl Zimmer Tags: your-feed-science Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) Immune System Proteins Ebola Virus AstraZeneca PLC Gamaleya Research Institute of Epidemiology and Microbiology Pfizer Inc Great Britain Russia Source Type: news

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, NJ (March 29, 2021) - Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate to African Union’s 55 member states with delivery beginning in the third quarter of 2021. AVAT also has the potential to order an additional 180 million doses, for a combined total of up to 400 million doses through 2022. The availability of the vaccine candidate is subject to its successful appr...
Source: Johnson and Johnson - March 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Statement on the Interim SAGE Recommendation Supporting the Use of the Johnson & Johnson COVID-19 Vaccine
New Brunswick, NJ (March 17, 2021) – We welcome the interim recommendation by the Strategic Advisory Group of Experts (SAGE) on Immunization for the World Health Organization (WHO) supporting the use of Johnson & Johnson’s single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in persons aged 18 years and above. SAGE advises WHO on global vaccine and immunization policies and its recommendations for use provide guidance on the use of vaccines supplied through the COVAX Facility, a global risk-sharing mechanism for pooled procurement and ...
Source: Johnson and Johnson - March 17, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
NEW BRUNSWICK, N.J., March 12, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percent reduction in symptomatic COVID-19 disease in participants who received the vaccine in comparison to participants give...
Source: Johnson and Johnson - March 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Commission (EC) has granted a Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. The CMA follows a Positive Opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).2 The CMA is valid in all 27 member states of the European Union (EU), plus Norway, Iceland and Liechtenstei...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion to recommend the Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percen...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

1,600 vaccinated in Guinea Ebola virus outbreak but more jabs needed: WHO
More than 1,600 people have received Ebola virus vaccinations in Guinea where four have died in a new outbreak, but more lifesaving jabs will be needed to contain the disease, the World Health Organization (WHO) said on Friday. (Source: UN News Centre - Health, Poverty, Food Security)
Source: UN News Centre - Health, Poverty, Food Security - March 5, 2021 Category: International Medicine & Public Health Source Type: news

Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use
March 5, 2021 - Johnson & Johnson (the Company) announced today that Health Canada has granted an Interim Order (IO) authorization for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.This decision was based on scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.Johnson & Johnson anticipa...
Source: Johnson and Johnson - March 5, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Another Covid-19 Threat: Health Care Workers Under Attack
A healthcare worker at a testing facility collects samples for the coronavirus at Mimar Sinan State Hospital, Buyukcekmece district in Istanbul, Turkey. Credit: UNDP Turkey/Levent KuluBy Joe Amon and Christina WillePHILADELPHIA, US, Mar 3 2021 (IPS) In the first months of the COVID-19 pandemic, at a certain hour of the evening, people in cities around the world opened their windows or stood on their rooftops and banged pots and rang bells. As the coronavirus spread and the number of deaths mounted, it was a moment for people distancing themselves from others to show solidarity and appreciation for the heroic work of health...
Source: IPS Inter Press Service - Health - March 3, 2021 Category: International Medicine & Public Health Authors: Joe Amon and Christina Wille Tags: Global Headlines Health TerraViva United Nations Source Type: news

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection agai...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
NEW BRUNSWICK, N.J., February 26, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial. “We are e...
Source: Johnson and Johnson - February 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Guinea: Hundreds of People Vaccinated Against Ebola
[RFI] More than 200 people in Guinea have been vaccinated against Ebola, just days after the arrival of some 11,000 doses of the Merck vaccine and just over a week since the West African country declared its first Ebola outbreak since the deadly epidemic from 2014 to 2016. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 26, 2021 Category: African Health Source Type: news

Guinea: Vital Ebola Vaccines Arrive After Dust Storm Delay
[RFI] Health officials are heading directly to Guinea's southeast region on Tuesday, after a special plane with 11,000 doses of Ebola vaccine landed late Monday night. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 23, 2021 Category: African Health Source Type: news

Guinea: Threat of Double Epidemic Worries Guineans As Ebola Vaccines Dispatched
[RFI] Some 11,000 vaccines for the Ebola virus are expected to arrive in Guinea this weekend, as a new outbreak has left five people dead and almost 200 contact cases. The stark reminder of the last West African outbreak comes with added complications of the Covid-19 crisis, which is already creating new challenges for health workers. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 20, 2021 Category: African Health Source Type: news

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 19, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered today includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. The Company’s rolling submission of clinical data to WHO is now complete.“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our u...
Source: Johnson and Johnson - February 19, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 16, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen-Cilag International N.V., has submitted a conditional Marketing Authorisation Application (cMAA) to the European Medicines Agency (EMA) seeking authorisation for its investigational single-dose Janssen COVID-19 vaccine candidate. The submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial.“Throughout Europe, there remains an urgent need for additional COVID-19 vaccines, and today’s submission is a significant step forward in ensuring the European Un...
Source: Johnson and Johnson - February 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Guinea Declares Ebola Epidemic as Neighboring Countries Act to Prevent Further Spread
DAKAR, Senegal — Guinea has officially declared it has an Ebola epidemic after at least three people have died and four others have been infected in the West African nation. Neighboring Sierra Leone and Liberia have put their citizens on high alert as the three West African nations battled the world’s deadliest Ebola outbreak from 2014 to 2016, which began in Guinea and in which more than 11,300 people died. Sierra Leone’s President Julius Maada Bio has flown to consult with Guinean President Alpha Conde. Guinea’s new Ebola outbreak occurred in N’Zerekore, in southern Guinea, where health offi...
Source: TIME: Health - February 16, 2021 Category: Consumer Health News Authors: CARLEY PETESCH / AP Tags: Uncategorized Source Type: news

Guinea tracks potential Ebola contacts as vaccination campaign begins in Congo
Guinea is tracking down people who potentially came in contact with Ebola patients after three people died of the disease, Health Minister Remy Lamah said on Monday. Meanwhile, the WHO said an Ebola vaccination campaign has begun in the Congolese city of Butembo. (Source: CBC | Health)
Source: CBC | Health - February 15, 2021 Category: Consumer Health News Tags: News/World Source Type: news

Africa: Organisations Announce Global Ebola Vaccine Stockpile for Quick Response
[WHO] The four leading international health and humanitarian organizations announced today the establishment of a global Ebola vaccine stockpile to ensure outbreak response. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 14, 2021 Category: African Health Source Type: news

COVID-19 Pandemic has Shown Humanity at its Best – & at its Worst
A health worker at a local health centre in Kinshasa, Democratic Republic of the Congo, prepares a vaccine injection. The dispatch of millions of COVID-19 vaccines to Africa started in February. Credit: UNICEF/Sibylle DesjardinsBy Tedros Adhanom GhebreyesusGENEVA, Feb 11 2021 (IPS) WHO and UNICEF have a long, deep and very special relationship. Neither of us could do what we do without the other. UNICEF’s success is WHO’s success, and we are proud to be your partner on so many issues: Ebola, polio, maternal health, nutrition, infection prevention and control, primary health care – the list is long. Neve...
Source: IPS Inter Press Service - Health - February 11, 2021 Category: International Medicine & Public Health Authors: Tedros Adhanom Ghebreyesus Tags: Development & Aid Education Global Globalisation Headlines Health Inequity Poverty & SDGs TerraViva United Nations Source Type: news

Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 4, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. The Company’s EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose vaccine met all primary and key secondary endpoints. The Company expects to have product available to ship immediately followi...
Source: Johnson and Johnson - February 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

NIH Director Francis Collins Is Fighting This Coronavirus While Preparing for the Next One
In May 2020, Dr. Francis Collins, the longtime head of the National Institutes of Health (NIH), was called to the White House to meet with Jared Kushner, the then President’s son-in-law and adviser, and Dr. Deborah Birx, the head of the White House Coronavirus Task Force. A few weeks earlier, Congress had given the NIH $1.5 billion to try to speed up the process of developing new diagnostic tests for COVID-19, and the White House, which was dubious about increasing the rate of testing, wanted to know more about what the NIH was doing. Collins is technically the boss of Dr. Anthony Fauci, but during the pandemic he ha...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe CO...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, wit...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Antibody highs and lows in survivors of Ebola
(University of Liverpool) A high proportion of survivors of Ebola experienced a resurgence in antibody levels nearly a year after recovery, a new University of Liverpool study has found. Published today in Nature, the finding hints that hidden reservoirs of virus could exist long after symptoms ease and has implications for monitoring programmes and vaccine strategies. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 27, 2021 Category: Infectious Diseases Source Type: news

Merck Stops Developing Both Of Its COVID-19 Vaccine Candidates
Merck, which previously made an Ebola vaccine, had been seen as a serious contender in the worldwide race to come up with an answer to the coronavirus.(Image credit: Budrul Chukrut/SOPA Images/LightRocket via Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - January 25, 2021 Category: Consumer Health News Authors: Bill Chappell Source Type: news

Johnson & Johnson ’s 1-Shot COVID-19 Vaccine Shows Promise in Early-Stage Trials
Johnson & Johnson’s experimental one-shot Covid-19 vaccine generated a long-lasting immune response in an early safety study, providing a glimpse at how it will perform in the real world as the company inches closer to approaching U.S. regulators for clearance. More than 90% of participants made immune proteins, called neutralizing antibodies, within 29 days after receiving the shot, according to the report, and all participants formed the antibodies within 57 days. The immune response lasted for the full 71 days of the trial. “Looking at the antibodies, there should be good hope and good reason that the va...
Source: TIME: Health - January 14, 2021 Category: Consumer Health News Authors: Riley Griffin / Bloomberg Tags: Uncategorized COVID-19 overnight wire Source Type: news